Skip to main content
. 2017 Nov 11;217(2):213–222. doi: 10.1093/infdis/jix582

Figure 3.

Figure 3.

Vaccine effectiveness (VE) for at least one dose against, (A) type-specific high-risk (hr) human papillomavirus (HPV) positivity and (B) pooled estimates.

The hr nonavalent HPV types included: HPV-16/18/31/33/45/52/58. All hrHPV types included: HPV-16/18/31/33/35/39/45/51/52/56/58/59. VE was corrected for: ethnicity, education level, recent sex partners, age at sexual debut, history of sexually transmitted infections, and hormonal contraceptives use.